Trial · NCT07886684
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
NCT07886684, Phase 1, Phase 2, Not yet recruiting, BioNTech SE
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn. Trials, record NCT07886684. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886684
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
- NCT number
- NCT07886684
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 173 participants, estimated
- Lead sponsor
- BioNTech SE
- Conditions
- Advanced Solid Tumors
- Interventions
- BNT3210
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part A only: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period | Up to 21 days from the initiation of first dose of study treatment | Defined as the first 21 days. By dose level. |
| Primary | Occurrence of treatment emergent adverse events (TEAEs) by grade, seriousness, and relatedness | Up to approximately 3 years from first dose of study treatment | From first dose of BNT3210 until 35 days after the last dose of BNT3210 or the start of new anti-cancer treatment, whichever is earlier. |
| Primary | Occurrence of dose interruptions, reductions, and discontinuation of BNT3210 due to TEAEs | Up to approximately 3 years from first dose of study treatment | From the time of initiation of the first dose of BNT3210 until administration of the last dose of BNT3210 or the start of new anti-cancer treatment, whichever is earlier. |
| Primary | Part B only: Objective response rate (ORR) | Up to approximately 3 years from first dose of study treatment | Defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] based on the investigator's assessment) is observed as best overall response. |
| Secondary | PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3210 | Up to approximately 42 days after last dose of study treatment | By dose level at treatment cycle. If data permits. |
| Secondary | PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3210 | Up to approximately 42 days after last dose of study treatment | By dose level at treatment cycle. If data permits. |
| Secondary | PK assessment: Time to Cmax (Tmax) derived from serum concentrations of BNT3210 | Up to approximately 42 days after last dose of study treatment | By dose level at treatment cycle. If data permits. |
| Secondary | PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3210 | Up to approximately 42 days after last dose of study treatment | By dose level at treatment cycle. If data permits. |
| Secondary | Part A only: ORR | Up to approximately 3 years from first dose of study treatment | Defined as the proportion of participants in whom a confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. |
| Secondary | Disease control rate | Up to approximately 3 years from first dose of study treatment | Defined as the proportion of participants in whom a confirmed CR or PR or stable disease (per RECIST v1.1 based on investigator's assessment) is observed as best overall response. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886684
GET https://conductscience.org/api/trials/v1/NCT07886684/registered